Myriad Genetics, Inc.MYGNNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P18
Within normal range
vs 3Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.57% |
| Q3 2025 | 10.16% |
| Q2 2025 | -6.91% |
| Q1 2025 | -14.60% |
| Q4 2024 | 12.98% |
| Q3 2024 | 5.17% |
| Q2 2024 | 8.84% |
| Q1 2024 | 18.57% |
| Q4 2023 | -12.50% |
| Q3 2023 | 13.21% |
| Q2 2023 | -5.78% |
| Q1 2023 | -3.85% |
| Q4 2022 | 14.15% |
| Q3 2022 | 0.99% |
| Q2 2022 | -4.25% |
| Q1 2022 | 27.71% |
| Q4 2021 | -11.70% |
| Q3 2021 | -3.59% |
| Q2 2021 | -15.58% |
| Q1 2021 | 0.00% |
| Q4 2020 | -100.00% |
| Q3 2020 | 1.15% |
| Q2 2020 | -11.68% |
| Q1 2020 | 4.79% |
| Q4 2019 | -11.74% |
| Q3 2019 | 1.91% |
| Q2 2019 | -2.79% |
| Q1 2019 | -4.02% |
| Q4 2018 | 6.16% |
| Q3 2018 | 19.21% |
| Q2 2018 | -4.32% |
| Q1 2018 | 10.12% |
| Q4 2017 | -5.62% |
| Q3 2017 | -5.32% |
| Q2 2017 | 6.82% |
| Q1 2017 | -5.38% |
| Q4 2016 | -4.12% |
| Q3 2016 | -0.51% |
| Q2 2016 | 13.37% |
| Q1 2016 | 2.99% |